Idera Pharmaceuticals is a biopharmaceutical company focused on the clinical development, and the commercialization, of drug candidates for rare disease indications characterized by patient populations with unmet medical needs. Co.'s focus is to identify and acquire rights to development and commercial stage rare disease programs through new business development opportunities, including additional alternatives. Co. is evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-Progressive Disease 1 antibody marketed as Opdivo® by Bristol Myers Squibb Company, and ipilimumab for the treatment of multiple solid tumors in a multicohort trial.
|
Free IDRA Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: IDRA Stock Forecast Based on Zacks ABR data; powered by Xignite |